Patents by Inventor Karl Bechtold
Karl Bechtold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230346780Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: May 4, 2023Publication date: November 2, 2023Inventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
-
Publication number: 20230338372Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: May 4, 2023Publication date: October 26, 2023Inventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
-
Patent number: 11633396Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: GrantFiled: August 24, 2022Date of Patent: April 25, 2023Assignee: Kudos Pharmaceuticals LimitedInventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
-
Publication number: 20230000862Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: August 24, 2022Publication date: January 5, 2023Inventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
-
Publication number: 20220249474Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: September 23, 2021Publication date: August 11, 2022Inventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
-
Publication number: 20200323847Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: April 30, 2020Publication date: October 15, 2020Inventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
-
Publication number: 20190365751Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: December 18, 2018Publication date: December 5, 2019Applicant: AstraZeneca UK LimitedInventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
-
Publication number: 20180133216Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: September 18, 2017Publication date: May 17, 2018Applicant: AstraZeneca UK LimitedInventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
-
Publication number: 20170173010Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: March 3, 2017Publication date: June 22, 2017Applicant: AstraZeneca UK LimitedInventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
-
Publication number: 20160008473Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: April 16, 2015Publication date: January 14, 2016Applicant: ASTRAZENECA UK LIMITEDInventors: Michael Karl Bechtold, Julie Kay Cahill, Katja Maren Fastnacht, Kieran James Lennon, Bernd Harald Liepold, Claudia Bettina Packhaeuser, Benedikt Steitz
-
Publication number: 20140066447Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: June 6, 2013Publication date: March 6, 2014Applicant: Astrazeneca UK, Ltd.Inventors: Michael Karl BECHTOLD, Julie Kay CAHILL, Katja Maren FASTNACHT, Kieran James LENNON, Bernd Harald LIEPOLD, Claudia Bettina PACKHAEUSER, Benedikt STEITZ
-
Patent number: 8475842Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1 -carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: GrantFiled: October 7, 2009Date of Patent: July 2, 2013Assignee: Astrazeneca ABInventors: Michael Karl Bechtold, Claudia Bettina Packhaeuser, Katja Maren Fastnacht, Bernd Harald Liepold, Benedikt Steitz, Julie Kay Cahill, Kieran James Lennon
-
Publication number: 20100098763Abstract: The present invention relates to a pharmaceutical formulation comprising the drug 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one in a solid dispersion with a matrix polymer that exhibits low hygroscopicity and high softening temperature, such as copovidone. The invention also relates to a daily pharmaceutical dose of the drug provided by such a formulation. In addition, the invention relates to the use of a matrix polymer that exhibits low hygroscopicity and high softening temperature in solid dispersion with 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one for increasing the bioavailability of the drug.Type: ApplicationFiled: October 7, 2009Publication date: April 22, 2010Applicants: Abbot GmbH & Co. KGInventors: Michael Karl Bechtold, Claudia Bettina Packhaeuser, Katja Maren Fastnacht, Bernd Harald Liepold, Benedikt Steitz, Julie Kay Cahill, Kieran James Lennon
-
Publication number: 20060287775Abstract: A method for controlling power sources or energy sinks on an energy accumulator, in particular for a motor vehicle, is disclosed. Conventional systems for power supply to the motor vehicle modules are often excessively used, in particular in utility vehicles when an optimal availability is required. The present method includes measuring parameters characterizing the charge of the accumulator, and transmitting the results of a measurement to a control unit and in generating control signals for the energy sinks or the power sources by a control unit. The method makes it possible to eliminate a frequent cause of a low availability in motor vehicles.Type: ApplicationFiled: July 27, 2004Publication date: December 21, 2006Applicant: SIEMENS AKTIENGESELLSCHAFTInventors: Karl Bechtold, Jurgen Wolf
-
Publication number: 20060287411Abstract: Highly concentrated, storage stable aqueous dispersions of a light stabilizer or of a mixture of a light stabilizer and an antioxidant, having an active substance content of more than 47% by weight, which comprise at least one nonionic wetting agent as dispersant and a polyglycol as solubilizer, and also 0.2% to 5% by weight of oleic acid as flow improver. Further constituents can be anionic wetting agents and biocides. These dispersions of the invention can be incorporated easily into coating compositions, e.g., an aqueous dispersion, an aqueous emulsion or an aqueous solution of a binder based on crosslinkable alkyd resin, acrylic resin, polyester resin or polyurethane resin.Type: ApplicationFiled: April 1, 2004Publication date: December 21, 2006Inventor: Karl Bechtold
-
Patent number: 6218451Abstract: The present invention relates to the use of a photoreactive and UV absorbing piperidine compound of the formula A below and of a mixture consisting of this piperidine compound and at least one selected UV absorber as light stabilizers in coating materials, preferably in automotive coating materials. The invention also provides a method of stabilizing coating materials against the degradation of the polymer material present in the coating material, as induced by the action of atmospheric oxygen, heat and/or UV light, and the coating materials themselves that are stabilized in this way.Type: GrantFiled: October 12, 1998Date of Patent: April 17, 2001Assignee: Clariant Finance (BVI) LimitedInventors: Karl Bechtold, Gilbert Ligner
-
Patent number: 6126861Abstract: The invention relates to novel compositions of photoreactive, UV-light absorbing, low molecular weight polyalkylpiperidines and non-photoreactive low molecular weight sterically hindered polyalkylpiperidines as well as to masterbatch compositions comprising the novel compositions. The invention relates further to a process for enhancing the light stability of organic material, the stabilized organic material and its use.Type: GrantFiled: October 13, 1998Date of Patent: October 3, 2000Assignee: Clariant Finance (BVI) LimitedInventor: Karl Bechtold
-
Patent number: 5976417Abstract: A composition, suitable for stabilizing a polymeric composition against the effects of light, comprisinga) an N-acylated 2,2,6,6-tetraalkylpiperidinyl group (hereinafter N-acylated HALS) containing compound; andb) an N-oxy-subst. 2,2,6,6-tetraalkylpiperidinyl group (hereinafter N-oxy-substituted HALS) containing compound.A further aspect of the invention relates to a composition, suitable for stabilizing a polymeric composition against the effects of light, comprisinga) an N-acylated 2,2,6,6-tetraalkylpiperidinyl-group-containing compound in which a spiro group is attached in the 4-position (hereinafter defined as component i); andb) an N-acylated 2,2,6,6-tetraalkylpiperidinyl-group-containing compound in which in the 4-position no spiro group is present (hereinafter defined as component ii).These compounds are suitable as light stabilizers in acid catalyzed lacquer system.Type: GrantFiled: March 30, 1995Date of Patent: November 2, 1999Assignee: Clariant Finance (BVI) LimitedInventors: Karl Bechtold, Gilbert Ligner, Rainer Wolf
-
Patent number: 5569539Abstract: New powder coatings or powder coating compositions comprisingA) a binder systemB) specific powder coating additivesC) at least one compound of formula I ##STR1## in which R.sub.1 is methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl or tert-butyl and optionallyD) additional compounds selected from the group consisting of antioxidants, UV-stabilizers, UV-absorbers, acid scavengers, radical scavengers, pigments, dyes, UV-quenchers, processing stabilizers, fillers, and tribocharging additivesexibit advantages during their production. Compounds according to formula I can be used as UV-absorbers and can be incorporated even in greater amounts and dispersed homogeneously at the manufacture of the powder coating compositions in an extruder. It is a further advantage of these compounds that they do not volatilize during stoving of the coatings.Type: GrantFiled: January 12, 1995Date of Patent: October 29, 1996Assignee: Sandoz Ltd.Inventors: Lajos Avar, Karl Bechtold, Rainer Wolf